Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12345678910111213...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Clear Cell Carcinoma Arising From Adenomyotic Cyst: A Case Report. (Pubmed Central) -  Nov 17, 2024   
    Five cycles of pembrolizumab and lenvatinib followed by four cycles of doxorubicin and cisplatin were ineffective. The patient died 13 months after the diagnosis of recurrence.
  • ||||||||||  Journal, PARP Biomarker:  Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib. (Pubmed Central) -  Nov 16, 2024   
    The use of both lenvatinib and PD-1 inhibitors with SBRT in patients with uHCC was associated with improved overall survival compared with lenvatinib and SBRT alone with a manageable safety profile. Exploiting the loss of drug-metabolizing enzyme gene activity in tumor cells following loss of heterozygosity could present a promising therapeutic strategy for targeted cancer treatment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, Metastases:  LEAP-014: first-line lenvatinib (Pubmed Central) -  Nov 16, 2024   
    P3
    Overall survival and progression-free survival are the dual primary end points. Clinical Trial Registration: NCT04949256 (ClinicalTrials.gov).
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase, Lenvima (lenvatinib) / Eisai, Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Journal, Tumor mutational burden, PARP Biomarker, IO biomarker, Pan tumor:  The Prognostic Value and Immunotherapeutic Characteristics of GFPT2 in Pan-cancer. (Pubmed Central) -  Nov 15, 2024   
    Clinical Trial Registration: NCT04949256 (ClinicalTrials.gov). Collectively, GFPT2 is potentially useful as a biomarker for prognostic prediction and immune infiltration in a variety of malignancies ,and could lead to exciting new approaches to personalized oncotherapy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical, Review, Journal:  Challenges in treating radioiodine-refractory thyroid cancer: a global perspective with a focus on developing nations in Latin America. (Pubmed Central) -  Nov 13, 2024   
    Identified predictors could guide risk stratification, aiding clinicians in tailored therapeutic approaches. Beyond the recognized need for prospective randomized clinical trials to determine the optimal first-line drug and the timing of molecular testing, this type of manuscript plays a pivotal role in stimulating discussions and disseminating comprehensive knowledge about the challenges associated with treating and monitoring patients with radioiodine-refractory thyroid carcinoma, especially in developing countries.
  • ||||||||||  Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  Efficacy and safety of adebrelimab combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma: a randomized controlled open-label phase II study (EUDRACT) -  Nov 10, 2024   
    P2,  N=36, Recruiting, 
    Beyond the recognized need for prospective randomized clinical trials to determine the optimal first-line drug and the timing of molecular testing, this type of manuscript plays a pivotal role in stimulating discussions and disseminating comprehensive knowledge about the challenges associated with treating and monitoring patients with radioiodine-refractory thyroid carcinoma, especially in developing countries. Not yet recruiting --> Recruiting
  • ||||||||||  Real-world outcomes on Spanish patients with metastatic renal cancer treated with first-line immunotherapy combinations (Exhibition) -  Nov 9, 2024 - Abstract #EMUC2024EMUC_477;    
    85% received nivolumab-ipilimumab as 1st treatment,11% pembrolizumab-axitinib,1.4% cabozantinib-nivolumab and 1% pembrolizumab-lenvatinib,leading those therapies to 61% of complete response,37% partial response,20% stabilitation and 28% disease progression.Median PFS was 13m for IO-IO and 9.4 for IO-TKI(HR 1.09 (95%CI 0.66-1.79),p=0.74) treated patients.Median OS was 24m for IO-IO and 16m for IO-TKI(HR 1.20(95%CI 0.67-2.13),p=0.54).Parameters significantly associated with OS included:ECOG 1?2,nephrectomy,bone/brain metastasis, neutrophilia,high neutrophil-lymphocyte index and lactacto-dehydrogenase.62% patients had any immune-related adverse events (iAEs)of which 42.2% were grade 2-4...Conclusions In Spanish pts with mRCC treated with IO-IO/IO-TKI in real life,no statistically significant differences were detected in PFS/OS depending on the treatment received.Grade 3/4 irAES detected in routine clinical practice were higher than described in pivotal studies.IMDC prognostic factors may require revision with the use of new immunotherapy combinations. Cabozantinib is effective in second line regardless of the treatment received in the 1st line for those who have not received it previously.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial (Exhibition) -  Nov 9, 2024 - Abstract #EMUC2024EMUC_459;    
    P3
    Materials & Methods Treatment-nai?ve pts (n=1069) with aRCC and a clear-cell component were randomized (1:1:1) to: L 20mg PO QD + P 200mg IV Q3W; or L 18mg + everolimus 5mg PO QD; or S 50mg PO QD (4 wks on/2 wks off)...In the L+P arm, 181 pts received subsequent anticancer regimens during survival follow-up (axitinib, n=43; cabozantinib, n=101)...This abstract was accepted and previously presented at the 2024 Annual Meeting. L+P (n=355) S (n=357) Pts with progressive disease and target lesions at baseline, n 176 195 Baseline sums of target lesion diameters (mm) Median (Q1, Q3) 56.7 (32.8, 117.0) 56.7 (38.2, 97.6) Sums of target lesion diameters (mm) at progression Median (Q1, Q3) 29.8 (12.2, 66.1) 42.8 (24.6, 84.3) Change in sums of target lesion diameters from baseline (%) Median (Q1, Q3) ?48.1 (?71.1, ?26.3) ?17.4 (?40.3, 0.8).
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed:  Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma (clinicaltrials.gov) -  Nov 7, 2024   
    P2,  N=26, Active, not recruiting, 
    Owing to SF's low immunogenicity and high reproducibility, this SF-based approach for TKI delivery holds substantial promise for advancing HCC systemic therapy. Recruiting --> Active, not recruiting
  • ||||||||||  The Association between Combination-Based Immunotherapy and Thrombotic Events in Patients with Metastatic Renal Cell Carcinoma (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_6796;    
    The IO/IO regimen was defined as ipilimumab plus nivolumab, while the IO/TKI regimen included nivolumab or pembrolizumab combined with a TKI such as axitinib, cabozantinib, or lenvatinib...Conclusion : There was no difference in the risk of venous and arterial thromboembolic events between mRCC patients receiving the IO/IO regimen and those receiving the IO/TKI regimen. However, patients on the IO/IO regimen had an increased risk of mortality compared to those on the IO/TKI regimen.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date:  Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus (clinicaltrials.gov) -  Nov 5, 2024   
    P2,  N=30, Recruiting, 
    Furthermore, the results of this investigation suggest that AFP holds promise as predictive biomarkers for this treatment strategy. Trial primary completion date: Aug 2024 --> Dec 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Checkpoint inhibition, Real-world evidence, Real-world, Metastases:  Real-world use of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. (Pubmed Central) -  Nov 4, 2024   
    Trial completion date: Mar 2025 --> Mar 2026 In an observational retrospective real-world database study, immune checkpoint inhibitors were used in 14.7% of patients with advanced or recurrent endometrial cancer across multiple lines of treatment, including after initial immune checkpoint inhibitor treatment.